ArticleJournal of neurological surgery. Part B, Skull base2026
Multi-Center, Multi-National Outcomes Following Endoscopic Endonasal Resection of Nonfunctional Pituitary Adenomas.
Article in Journal of neurological surgery. Part B, Skull base, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Nonfunctioning pituitary adenomas (NFPA) are common, benign lesions of the pituitary gland. The endoscopic endonasal approach (EEA) has improved their treatment. Large multi-center data across different healthcare systems on outcomes following EEA resection of NFPA are limited. We aimed to provide highly generalizable benchmark outcomes from an international, multi-center review of EEA for NFPA resection. Methods: Institution-level data on symptoms, tumor and intraoperative characteristics, complications, and long-term outcomes were obtained from four tertiary pituitary centers located in the United States (2), Italy (1), and Austria (1). Means and weighted averages were used to generate descriptive statistics of patient characteristics and outcomes. Results: A total of 1,097 patients who underwent EEA for NFPA were included (mean age: 55.3 years). Presenting symptoms included vision loss (55.2%) and headache (42.1%). The most common preoperative endocrinopathies were hyperprolactinemia (26%) and hypothyroidism (18%). The gross total resection rate was 66%. Patients presenting with headache and visual symptoms experienced improvement (81 and 89%, respectively). Common complications included delayed hyponatremia (7.5%), transient arginine vasopressin deficiency (AVP-D; 6.6%), cerebrospinal fluid leak (3.5%), new endocrinopathy (3.5%), and new cranial nerve palsy (0.8%). There were no instances of carotid artery injury. Stroke (0.4%) and death (0.1%) were exceedingly rare. During the mean follow-up of 30 months, <5% of patients underwent reoperation or radiation-based treatments. Conclusion: In this large, international series, EEA proved a safe and effective intervention that was generalizable across centers in the United States and Europe. Severe complications were rare, and significant improvements in headache and vision loss were noted in most patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.